Back to Research Home
MEDPMedpace Holdings Inc
Health Care · Biotechnology: Commercial Physical & Biological Resarch · Large
$669.20+2.33%
As of 23 Oct 2026Mkt cap $16.6B
Stage 13
WAIT
Fundamentals
54.9/75
Technical
5.4/15
Independent
60.2/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- +7.8%
- 3M
- +13.5%
- 6M
- +63.0%
- 1Y
- +22.4%
Financials & valuation
Cached filing evidence · as of 2026-10-22
Valuation
- P/E
- 37.1xHist median 29.2x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 29.6x
- FCF yield
- 3.4%
Quality
- ROIC
- 220.0%
- Operating margin
- 21.1%
- FCF margin
- 26.9%
- Current ratio
- 0.7x
Growth
- Revenue growth
- +20.0%Latest FY YoY
- Revenue CAGR
- +22.0%
- EPS CAGR
- +33.5%
- FCF CAGR
- +30.5%
Capital
- Share-count trend
- −3.7%3Y annualised
- Net cash
- $360M-0.5x OCF
Annual trend
- CAGR 2021–2025
- +22.0%
- Latest · 2025
- $3B
- YoY
- +20.0%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
elevated earnings event risk blocks an independent BUY decision
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2027-02-08
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-22
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded